Sample Report
This Is What a Psychiatric Medication Report Looks Like
See how CYP2D6 and CYP2C19 results map to antidepressants, ADHD medications, and mood stabilizers. Your report follows the same structure — personalized to your genetics.
What's Inside Your Report
Every Psychiatric Medication Report includes these sections, covering CYP2C19 and CYP2D6 with medications mapped by condition.
Risk Snapshot
Your overall psychiatric medication genetic risk level with significant and moderate finding counts.
90-Second Summary
Top impact areas explained in plain language with the medications affected and when this report matters.
Condition-Based Grouping
Medications organized by condition — Depression & Anxiety, ADHD, Bipolar — with action levels for each.
Decision Table
A compact reference with every affected medication, your gene result, CPIC level, and suggested consideration.
Clinician Pocket Summary
A one-page clinical reference your prescriber can review in under 60 seconds.
Detailed Findings
Full gene-by-gene analysis with diplotype, activity score, affected medications, and CPIC evidence level.
Psychiatric Medication Report — Full Sample
Sample Data — Not Your Results
Psychiatric Medication Report
February 21, 2026
Based on CPIC psychiatric pharmacogenomics guidelines
Your genetics suggest 2 psychiatric medication interactions requiring attention and 1 to review with your prescriber.
Your body processes certain psychiatric medications more slowly than most people, which means side effects may appear sooner and feel stronger than your prescriber would typically expect. Your ADHD medication response may also differ from what is typical. This report identifies which specific medications are affected and what to discuss with your prescriber.
Real-World Implications
Lexapro, Celexa, and Zoloft may cause side effects faster than expected
Affects: escitalopram (Lexapro), citalopram (Celexa), sertraline (Zoloft)
If you have started Lexapro, Celexa, or Zoloft and experienced nausea, headaches, insomnia, or other side effects that came on too fast or too strong — your genetics explain why. Your body clears these specific SSRIs much more slowly, so standard doses produce significantly higher drug levels than your prescriber would expect.
Why this happens
Your CYP2C19 result is *2/*2 (Poor Metabolizer).
What clinicians sometimes consider
- CPIC recommends reduced starting doses for escitalopram and citalopram in CYP2C19 poor metabolizers
- Alternative SSRIs metabolized primarily by CYP2D6 (e.g., paroxetine, fluoxetine) may be considered
Antidepressant doses may feel slightly too strong at first
Affects: paroxetine (Paxil), fluoxetine (Prozac), venlafaxine (Effexor)
Your body clears certain antidepressants more slowly than most people. You may notice that side effects are more pronounced during the first weeks of treatment, or that doses that work well for others feel too strong for you. This is manageable — but your prescriber should know, so they can start lower and adjust.
Full analysis and clinician considerations in your report
Strattera (atomoxetine) may require more adjustment than typical
Affects: atomoxetine (Strattera)
Your body clears atomoxetine somewhat more slowly than average. You may be more sensitive to side effects during the first weeks of treatment and may need a longer adjustment period to find the right dose.
Full analysis and clinician considerations in your report
2 additional scenarios with full explanations in your report
My Risk Snapshot
High Pharmacogenomic ImpactYour overall medication genetic risk is High based on current CPIC evidence.
Do this next: Bring this report to your prescriber before starting or changing medications.
In an ER or urgent care visit, this report can speak for you when you can’t.
Your Medication DNA — 90 Second Summary
Top Impact Areas
CYP2C19 — Poor Metabolizer
Affects: 5 psychiatric medications in this category
What this means: You break down these medications much more slowly than most people.
If you take these meds: Discuss with your prescriber about dose adjustment or alternative medications.
CYP2D6 — Intermediate Metabolizer
Affects: 5 psychiatric medications in this category
What this means: You break down these medications slightly differently than average.
If you take these meds: Mention this result when starting new medications in this category.
Gene Impact Overview
Your CYP2C19 result is *2/*2 (Poor Metabolizer).
Your CYP2D6 result is *1/*4 (Intermediate Metabolizer).
When This Report Matters
- ●If you are starting or switching an antidepressant (SSRI/SNRI) — share this report with your prescriber so they can factor in your genetics.
- ●If you are prescribed a tricyclic antidepressant (TCA) — these medications have narrow dosing windows and your genetics may be especially relevant.
- ●If you are starting atomoxetine for ADHD — your CYP2D6 result may affect how quickly you metabolize this medication.
- ●Bring this report to your next psychiatric appointment — these results stay relevant across your lifetime, even as medications change.
Based on CPIC clinical guidelines. This does not replace professional medical advice.
Clinician Pocket Summary
High Pharmacogenomic ImpactSignificant: 1|Moderate: 1|Genes tested: 2
| Gene | Diplotype | Phenotype | Key Medications | Suggested Action |
|---|---|---|---|---|
| CYP2C19 | *2/*2 | Poor Metabolizer | escitalopram, citalopram, sertraline, vortioxetine | Consider alternatives or dose adjustment |
| CYP2D6 | *1/*4 | Intermediate Metabolizer | paroxetine, atomoxetine, venlafaxine, nortriptyline | Review dosing; monitor closely |
Scope: This report evaluates CYP2D6 and CYP2C19 only. No additional genes are included.
Based on CPIC psychiatric pharmacogenomics guidelines. Confirm all medication decisions with clinical assessment and therapeutic monitoring.
How Your DNA Affects Psychiatric Medications
Depression & Anxiety
+6 more medications checked across conditions in your full report
Compact Decision Table
| Medication | Gene Result | Status | CPIC | Suggestion | Why |
|---|---|---|---|---|---|
| amitriptyline (Elavil) | CYP2C19 *2/*2 + CYP2D6 *1/*4 | Poor Metabolizer / Intermediate Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| citalopram (Celexa) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| escitalopram (Lexapro) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| sertraline (Zoloft) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
| vortioxetine (Trintellix) | CYP2C19 *2/*2 | Poor Metabolizer | Level A | Consider alternatives or adjusted dosing | Drug levels may build up |
Full medication-by-medication breakdown in your report — 6 more medications
Detailed Findings
Result: Poor Metabolizer
Diplotype: *2/*2
Confidence: high
Metabolizer Scale
▲ You are here: Poor Metabolizer
Your CYP2C19 genotype (*2/*2) indicates you are a Poor Metabolizer with an activity score of 0.0. You may process escitalopram, citalopram, sertraline, vortioxetine, amitriptyline differently than average. CPIC guidelines recommend discussing dosing adjustments with your prescriber.
- Affected medications: escitalopram, citalopram, sertraline, vortioxetine, amitriptyline
- What to discuss: Discuss with your prescriber before starting or changing these medications.
- Evidence: CPIC Level A
References: PMID:23486447, PMID:25974703, PMID:37032427
Result: Intermediate Metabolizer
Diplotype: *1/*4
Your CYP2D6 genotype (*1/*4) indicates you are an Intermediate Metabolizer with an activity score of 1.0.
Full finding with affected medications, metabolizer scale, and CPIC recommendation in your report
1 additional finding with metabolizer scale, affected medications, and CPIC recommendations in your personalized report
Limitations & Disclaimers
- This report covers CYP2D6 and CYP2C19 only — these are the two genes with the strongest pharmacogenomic evidence for psychiatric medications. Other genes may also play a role.
- CYP2D6 gene duplications and deletions cannot be reliably detected from consumer DNA data. If CYP2D6 metabolism is a clinical concern, laboratory-grade sequencing is recommended.
- Psychiatric medication response depends on many factors beyond genetics, including diagnosis, comorbidities, other medications, lifestyle, and therapeutic monitoring. Genetics is one input among many.
- Do not stop, start, or change any psychiatric medication based solely on this report. All medication changes should be made under the supervision of a licensed prescriber.
- This report is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
- Recommendations are based on current CPIC guidelines and may be updated as new evidence emerges.
This is a sample report generated with fictional data for demonstration purposes. Your actual report will reflect your personal genetic results.
Get your personalized psychiatric report
Upload your 23andMe or AncestryDNA raw data. Your Psychiatric Medication Report is $59 — one-time, no subscription.
Get Your Psychiatric Report — $59Free Upload vs. Psychiatric Medication Report
Everyone gets free trait insights after uploading. The Psychiatric Report maps your CYP2D6 and CYP2C19 results to specific antidepressants, ADHD medications, and mood stabilizers.
Free with upload
- 9 trait insights (caffeine, lactose, etc.)
- CYP2D6 and CYP2C19 metabolizer status
- Which psychiatric medications are affected
- Condition-based grouping (depression, ADHD)
- CPIC dosing recommendations
- Clinician pocket summary
Psychiatric Medication Report
$59- Everything in free, plus:
- 18 psychiatric medications mapped to your genes
- Organized by condition (depression, ADHD, anxiety)
- Per-drug CPIC recommendations
- Shareable clinician pocket summary
- Risk snapshot and decision table
Psychiatric Pharmacogenomics from DNA You Already Have
The Psychiatric Medication Report is $59 using raw data from 23andMe or AncestryDNA. Clinical psychiatric pharmacogenomic testing — such as GeneSight — typically costs several hundred to over a thousand dollars, requires a prescription and new sample, and may not be covered by insurance.
Both approaches reference CPIC clinical guidelines for CYP2D6 and CYP2C19. The difference: you already have the data.
Built on CPIC Guidelines
Every finding cites evidence from the Clinical Pharmacogenetics Implementation Consortium (CPIC) — the same guidelines used by hospitals and pharmacies worldwide. Only Level A (strong) and Level B (moderate) evidence is included.
For educational and informational purposes only. Not a substitute for clinical pharmacogenomic testing or medical advice. See our limitations page for details.
Ready to See Your Psychiatric Medication Results?
Upload your 23andMe or AncestryDNA raw data. Your personalized Psychiatric Medication Report is $59 — one-time, no subscription.